Tindamax Side Effects
Generic Name: tinidazole
Please note - some side effects for Tindamax may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
Side Effects of Tindamax - for the Consumer
Tindamax
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Tindamax:
Seek medical attention right away if any of these SEVERE side effects occur when using Tindamax:Constipation; diarrhea; dizziness; general body discomfort; headache; loss of appetite; metallic/bitter taste in mouth; nausea; stomach pain; tiredness; vomiting; weakness.
TopSevere allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); abnormal skin sensations (prickling, tingling); depression; fever, chills, or persistent sore throat; hoarseness; irregular heartbeat; numbness or loss of feeling in the hands or feet; pounding in the chest; red, swollen, blistered, or peeling skin; seizures; shortness of breath; unusual bruising or bleeding ; vaginal irritation or discharge.
Tindamax Side Effects - for the Professional
Tindamax
Most common adverse reactions for a single 2 g dose of tinidazole (incidence >1%) are metallic/bitter taste, nausea, weakness/fatigue/malaise, dyspepsia/cramps/epigastric discomfort, vomiting, anorexia, headache, dizziness and constipation (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Side Effects by Body System
Gastrointestinal
Gastrointestinal side effects have included metallic/bitter taste (3.7% following a 2 g single dose and 6.3% following multi-day dosing), nausea (3.2% following a 2 g single dose and 4.5% following multi-day dosing), anorexia (1.5% following a 2 g single dose and 2.5% following multi-day dosing), dyspepsia/cramps/epigastric discomfort (1.8% following a 2 g single dose and 1.4% following multi-day dosing), vomiting (1.5% following a 2 g single dose and 0.9% following multi-day dosing), constipation (0.4% following a 2 g single dose and 1.4% following multi-day dosing), tongue discoloration, stomatitis, diarrhea, decreased appetite, and flatulence. Furry tongue and pharyngitis have been reported rarely.
Nervous system
Nervous system side effects have included weakness/fatigue/malaise (2.1% following 2 g single dose and 1.1% following multi-day dosing), dizziness (1.1 % following 2 g single dose and 0.5% following multi-day dosing), convulsions, transient peripheral neuropathy (including numbness and paresthesia), vertigo, ataxia, giddiness, insomnia, and drowsiness.
Oncologic
Oncologic side effects have included mutagenicity in animal studies. Tinidazole has tested positive for genotoxicity in in vivo studies.
Hepatic
Hepatic side effects have included raised transaminase levels and at least one case report of possible hepatitis.
A possible case of hepatitis was reported in a 4-year-old girl after receiving tinidazole 625 mg orally as a single dose treatment for Giardia. The patient returned to the clinic 6 days following tinidazole therapy with concerns of a 3-day history of progressive ankle swelling. Upon examination she was found to have a 3 g weight gain, marked edema of legs (up to knees), periorbital edema, abdominal distension, ejection flow murmur, liver palpable 6 cm below right coastal margin, no palpable spleen, and clinical evidence of ascites. Laboratory results, upon this admission, were hemoglobin 112 g/L, white cell count 5.2 x 10(9)/L, ESR 14 mm in one hour, sodium 145 mmol/L, potassium 2.6 mmol/L, urea 2.2 mmol/L, total protein 55 g/L, albumin 31 g/L, bilirubin 8 micromoles/L, gamma-glutamyltransferase (GGT) 50 units/L, aspartate aminotransferase (AST) 231 units/L, and creatine phosphokinase 1498 units/L. A chest X-ray, abdominal X-ray, and electrocardiogram showed no abnormalities. Tests for hepatitis A, hepatitis B, leptospirosis, cytomegalovirus, and Epstein-Barr virus were all negative. The patient's parents denied any known contact with infectious hepatitis. The patient was treated with potassium and spironolactone. The patient never became jaundiced. Two weeks later, all serum electrolyte levels and laboratory tests had returned to normal values, edema was absent, liver was palpable 2 cm below right costal margin, and the spleen could just be felt.
Musculoskeletal
Musculoskeletal side effects have included arthralgias, myalgias, and arthritis.
Hypersensitivity
Hypersensitivity side effects have included urticaria, pruritus, rash, flushing, sweating, dryness of mouth, fever, burning sensation, thirst, salivation, and angioedema. Severe acute hypersensitivity reactions (including urticaria, pruritis, angioedema, Stevens-Johnson syndrome, and erythema multiforme) during initial or subsequent tinidazole exposure have been reported during postmarketing experience.
Ten patients were reported to have hypersensitivity reactions occurring on the same day of oral tinidazole administration. Nine patients were adults receiving 2 g as a single-dose. One patient was a 5-year-old girl receiving 500 mg as a single-dose. Nine reactions were severe and atropine was administered as part of the treatment. The reactions were characterized by urticaria; facial, periorbital, or laryngeal edema; hypotension; bronchospasm; and dyspnea. All patients recovered without further incidence. Note, at the time of these reactions the oral tablets contained tartrazine. It has been hypothesized that the tartrazine was the causative agent for these reactions. However, none of the patients had a history of asthma, atopy, or sensitivity to aspirin or aspirin-like products.
Renal
Renal side effects have included darkened urine and urine abnormality.
Cardiovascular
Cardiovascular side effects have included palpitations.
Hematologic
Hematologic side effects have included transient neutropenia and transient leukopenia. Reversible thrombocytopenia has been reported rarely.
Genitourinary
Genitourinary side effects have included increased vaginal discharge, urinary tract infection, dysuria, vulvovaginal discomfort, vaginal odor, menorrhagia, female genital pruritus, and Candida vaginitis.
Respiratory
Respiratory side effects have included upper respiratory tract infection. Bronchospasm and dyspnea have been reported rarely.
Psychiatric
Psychiatric sides effects have included rare reports of depression.
Other
Other side effects have included headache (1.3% following a 2 g single dose and 0.7% following multi-day dosing), Candida overgrowth, oral candidiasis, and pelvic pain. Confusion and coma have been reported rarely.
Dermatologic
In a study involving 450 patients with fixed drug eruptions, 8 patients were found to have oral tinidazole as the probable causative agent. The fixed drug eruptions varied as to duration, shape and size, symptoms, number of lesions, and body site(s) affected. The study did not break these factors down for each individual causative agent.
Dermatologic side effects have included reports of fixed drug eruption.
General
General side effects have included severe toxic reaction (1 case report) following intravenous administration of tinidazole.
A 44-year-old man experienced a severe toxic reaction following administration of tinidazole 1600 mg intravenously over 80 minutes. Within 15 minutes following end of the infusion he fainted and was unconscious for about 10 seconds. The patient experienced some spasms of his left arm, without generalized convulsions, while resuming consciousness. Pharmacologic treatment was not necessary during or following the attack. Low blood pressure, intense nausea, sleepiness, and exhaustion followed the attack and lasted for several hours. The patient's condition gradually improved and he was completely recovered 6 hours after start of attack. Blood samples following infusion showed serum tinidazole level of 35.4 mg/L, normal immunoglobulin E level, and a transient fall in the concentration of complement factor C3.
TopMore resources:
Tindamax - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
A to Z Drug List
Drugs by Condition
Drug Side Effects
Natural Products
Community Forums
Interactions Checker
MedNotes
Support Groups
Drug Image Search
Phonetic Search
FDA Drug Alerts
New Drug Approvals
New Drug Applications
Clinical Trial Results
Medical Encyclopedia
News Feeds
Drugs by Classification
Patient Care Notes
Drug Imprint Codes
Medical Dictionary
Subscribe to our popular newsletter containing a regular roundup of medication news, alerts and new drug approvals.
